OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum
OSR Holdings (NASDAQ:OSRH) received a 180-calendar-day Nasdaq extension to regain compliance with the $1.00 minimum bid price rule, extending the cure period to August 31, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OSR Holdings (NASDAQ:OSRH) received a 180-calendar-day Nasdaq extension to regain compliance with the $1.00 minimum bid price rule, extending the cure period to August 31, 2026. Trading of common stock remains uninterrupted under ticker OSRH.
The company reiterated strategic priorities: a potential VXM01 licensing transaction with USD 30 million upfront plus up to USD 815 million in milestones, and a medical device platform merger consolidating RMC and Woori IO.
Positive
- Nasdaq extension granted through August 31, 2026
- VXM01 licensing structured for USD 30M upfront
- Potential up to USD 815M in milestone payments
- Progressing RMC–Woori IO medical device consolidation
Negative
- Current minimum bid price deficiency under Nasdaq Rule 5550(a)(2)
- Must achieve $1.00 closing for ten consecutive business days
- Company cited unusual trading dynamics impacting share price
Details
News Market Reaction – OSRH
On Mar 5, the day this news came out, OSRH closed 14.67% above the previous close.
Data tracked by StockTitan Argus for the Mar 5 session.
Key Figures
- Nasdaq extension length
- 180 calendar days
- Additional period to regain $1.00 bid compliance
- Bid price requirement
- $1.00 per share
- Minimum closing bid for Nasdaq Listing Rule 5550(a)(2)
- Compliance window end
- August 31, 2026
- Deadline to restore bid-price compliance under new extension
- Required trading streak
- 10 business days
- Consecutive days at or above $1.00 closing bid
- VXM01 upfront value
- USD 30 million
- Proposed global license consideration (cash and digital assets)
- VXM01 cash upfront
- USD 15 million
- Portion of proposed VXM01 upfront in cash
- VXM01 digital assets
- USD 15 million
- Portion of proposed VXM01 upfront in digital assets
- Potential milestones
- USD 815 million
- Proposed VXM01 milestone payments in licensing initiative
Historical Context
-
CEO update on Nasdaq timing plus VXM01 licensing and device-merger strategy.
-
Completion of Woori IO acquisition and review of combining device subsidiaries.
-
FDA clarification enabling two-phase commercialization for Woori IO wearables.
-
Appointment of new Vaximm CSO to advance VXM01 and platform R&D.
-
Binding term sheet for global VXM01 license with upfront and milestone structure.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
milestone payments financial
bid price financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BELLEVUE, WASHINGTON / ACCESS Newswire / March 5, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding company advancing innovative biomedical technologies, today announced that it has received written notification from The Nasdaq Stock Market LLC granting the Company an additional 180-calendar-day extension to regain compliance with Nasdaq Listing Rule 5550(a)(2), the minimum
The extension provides the Company until August 31, 2026, to satisfy the rule by achieving a closing bid price of at least
Strategic Continuity and Execution
As outlined in the CEO's February 2026 Statement to Shareholders, the Company remains focused on strengthening its capital structure and advancing near-term value catalysts, including:
VXM01 Licensing Initiative: Subsidiary Vaximm AG continues to advance discussions toward a global licensing transaction for lead immuno-oncology asset VXM01, structured to include USD 30 million in upfront consideration (USD 15 million cash and USD 15 million digital assets) and up to USD 815 million in milestone payments.
Medical Device Platform Merger: Progressing consolidation of RMC and Woori IO to form an integrated medical technology and distribution platform, while advancing international partnership interest in Woori IO's non-invasive glucose monitoring technology.
In its prior disclosure regarding the minimum bid price deficiency, the Company noted unusual trading dynamics impacting its share price. While management continues to monitor market activity and safeguard shareholder interests, the Company believes that disciplined execution of its strategic initiatives and continued strengthening of underlying fundamentals represent the most effective path to enhancing long-term shareholder value.
"We view this extension as a clear operational runway for our strategic initiatives to mature and translate into tangible shareholder value," said Tim Smith, Head of Investor Relations. "With multiple near-term catalysts advancing, we believe OSR Holdings is well positioned to strengthen its capital markets profile and return to compliance through disciplined execution."
The Company will continue to monitor its bid price closely and remains confident in its ability to execute its strategic initiatives and restore full compliance during the extension period.
About OSR Holdings, Inc.
OSR Holdings is a healthcare-focused holding company dedicated to accelerating innovation across immuno-oncology, regenerative biologics, and medical technologies. Through strategic investment and operational oversight, the Company seeks to develop and commercialize transformative healthcare solutions while maintaining a strong commitment to corporate governance and long-term shareholder value. Learn more at www.OSR-Holdings.com
Contact
Media & Investor Contacts
OSR Holdings, Inc.
Investor Relations
Email: ir@osr‑holdings.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the Company's ability to regain compliance with Nasdaq listing requirements; the timing, structure, and potential completion of any licensing transaction involving VXM01; anticipated upfront or milestone consideration (including digital asset components); and the execution of the Company's strategic initiatives. These forward-looking statements involve risks and uncertainties, including market conditions, regulatory developments, transaction execution risk, volatility in digital asset markets, and other factors that could cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statements except as required by law.
SOURCE: OSR Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.